Last reviewed · How we verify
Intravenous Paricalcitol
At a glance
| Generic name | Intravenous Paricalcitol |
|---|---|
| Also known as | Zemplar |
| Sponsor | The University of Hong Kong |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer (PHASE1)
- The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients (NA)
- A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients (PHASE4)
- Intravenous Paricalcitol in Chronic Hemodialysis Patients (PHASE4)
- A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis (PHASE4)
- Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous
- Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years
- Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Paricalcitol CI brief — competitive landscape report
- Intravenous Paricalcitol updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI